一家大规模流感疫苗生产基地计划于年内在深圳全面建成投产，预计可年产2500万剂季节性流感疫苗。投资兴建方——全球最大流感疫苗生产企业法国赛诺菲公司日前在上海宣布了这一消息。

A large-scale flu vaccine production base in shenzhen comprehensive plan in years completed and put into operation,Can be expected to an annual output of 25 million agent seasonal influenza vaccine.Invest in the construction of the party - the world's largest flu vaccine production enterprise French sanofi company in Shanghai has announced the news.

　　“除季节性流感疫苗之外，这个基地还能生产禽流感疫苗以及H1N1甲型流感疫苗，足以应对流感大流行。”据赛诺菲公司亚洲区高级副总裁龙贤礼介绍，新厂所产疫苗将投放全球市场，但会根据每年流感流行状况优先满足中国市场需求。

"In addition to seasonal influenza vaccine outside,The base can also bird flu vaccine production and H1N1 influenza a vaccine,Enough to deal with the flu pandemic."According to the sanofi Asia company senior vice President LongXianLi is introduced,The new factory produce vaccine will put on the global market,But, according to an annual flu epidemic situation gives priority to the Chinese market demand.

　　2007年，中法签署协议，由赛诺菲在深圳投资7亿元人民币兴建一座现代化的疫苗生产基地。龙贤礼说：“中国流感疫苗市场潜力巨大。目前，在发达国家，仅老年人的流感疫苗接种率就达60%以上，而在中国还不到1%。”

In 2007,,Method in the agreement,By sanofi in shenzhen investment is 700 million yuan RMB to build a modern vaccine production base.LongXianLi said:"China's huge market potential in the influenza vaccine.At present,In developed countries,Only the influenza vaccine rate reached 60%,In China is less than 1%."

　　赛诺菲同时宣布了另外三个将于年内投产的对华投资项目——杭州制药工厂、杭州健康药业工厂和南昌梅里亚动物保健工厂，总投资超过11亿元人民币。(记者 张晓松)

Sanofi also announced another three years of production in China investment projects - hangzhou pharmaceutical factory/Hangzhou health pharmaceutical factories and nanchang merial limited animal health factory,With a total investment of more than 1.1 billion yuan RMB.(Reporter ZhangXiaoSong)